Main contents starts here
Overview
Takeda has created numerous pharmaceutical products, including the four international strategic products (Leuprorelin Acetate, Lansoprazole, Candesartan Cilexetil, Pioglitazone Hydrochloride), which are distributed in many countries around the world. In the hopes of continuously developing superior pharmaceutical products to follow these and delivering at the earliest possible date the new drugs that are eagerly awaited by patients, we are, being guided by the MPDRAP (Marketing, Production, Development, Research, Alliance, Patent) strategy, committed to the development of new drugs by focusing our management resources on the four core therapeutic areas of: life-style related diseases; oncology and urological diseases; central nervous system diseases, and gastroenterological diseases.
R&D News
- April 30, 2008
Sucampo Pharmaceuticals Obtains FDA Approval for AMITIZA® for the Treatment of Irritable Bowel Syndrome with Constipation in Adult Women - April 10, 2008
Presentation Materials about Acquisition of Millennium Pharmaceuticals, Inc. - April 10, 2008
Takeda to Acquire Millennium for Us$25.00 Per Share in an All Cash Tender Offer Valued at $8.8 Billion - April 4, 2008
Takeda Wins Definitive Decision in Patent Infringement Litigation on Appeal against an ANDA Filer for Generic ACTOS® - April 1, 2008
Launch of Takeda Bio Development Center Limited
Latest Publications of Takeda Research Laboratories
 |
R&D At a Glance
| Main R&D Facilities | The Tsukuba Research Center (Tsukuba, Japan) |
| The Osaka Research Center (Osaka, Japan) | |
| Takeda Research Investment, Inc. (New York, NY, U.S.) | |
| Takeda San Diego, Inc. (San Diego, CA, U.S.) | |
| Takeda San Francisco, Inc. (San Francisco, CA, U.S.) | |
| Takeda Cambridge Limited (Cambridge, U.K.) | |
| Takeda Singapore Pte Limited (Singapore) | |
| Japan Deveropment Center | |
| Takeda Global Research & Development Center, Inc. (Deerfield, IL. U.S.) | |
| Takeda Global Research & Development Centre(Europe), Ltd. (London, U.K.) | |
| R&D Investment | ¥275.8billion ($2,758million) (FY2007) |
| Royalty Income | ¥50.7billion ($507million) (FY2007) |
| Core Therapeutic Areas |
Life style-related diseases, Oncology & Urological diseases, Central nervous system diseases, Gastroenterological diseases |
| Product Pipeline |
Takeda discloses ethical drugs under development that have reached phase I or higher status in at least one country among Japan, the U.S. and EU |
Note: The US dollar amounts represent translations of Japanese yen, for conbeniense only, at the rate of ¥100=US$1 approximate exchange rate at March 31, 2008.